Biopharmaceutical company Enterprise Therapeutics Ltd reported on Tuesday the receipt of up to USD7m in funding for the development of novel chloride channel modulator ETD002 from the Cystic Fibrosis Foundation's Therapeutics Development Award programme.
CF is a devastating and life-limiting genetic disease. CF patients have a significant reduction in the hydration of their airway mucus, leading to failed clearance, a high incidence of infections and rapid decline in lung function.
The company added that the milestone-related funding will support clinical development up to the end of Phase 2 for ETD002, a first-in-class TMEM16A potentiator with the potential to treat all persons with cystic fibrosis (CF), independent of their cystic fibrosis transmembrane conductance regulator (CFTR) mutation type. The ETD002 programme is targeting the calcium-activated chloride ion channel TMEM16A, resulting in an increased anion and fluid flow into the airways, thinning the mucus and increasing its clearance from the airways.
This funding will enable critical clinical research to be undertaken on the company's novel TMEM16A programme as well as highlight the potential of chloride channel modulation via alternative channels to deliver innovative and effective treatments for all CF patients.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera